Sohini Das

Tata Motors CV biz switches gear from trucks to wider mobility highway

Digital platforms, international operations and mobility services are emerging as key growth drivers as Tata Motors Commercial Vehicles seeks to reduce cyclicality

A difficult year: El Niño concerns trigger earnings risk for India Inc

India's southwest monsoon from June 1 to June 23 has been almost 43% below normal, among its worst performances in the last several years

Hyderabad firm builds over ₹400 crore pharma biz, without a factory

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

India-UK trade pact opens premium vehicle market, protects EV push

JLR says local manufacturing plans remain unchanged as India opens its premium vehicle market to British imports while protecting lower-cost EV segments

JLR doubles down on North America amid slowing momentum in China

Jaguar will go all-electric, while Range Rover and Defender retain hybrid and combustion options as JLR pivots towards North America and future growth markets

India's pharma market gets a lift from rising volumes, not just prices

Chronic therapies and GLP-1 adoption help broaden growth drivers as the market expands over 10 per cent in April and May

India breaks into the top 15 markets for Mercedes-Benz, says Mathias Geisen

India is now among Mercedes-Benz's top 15 global markets and top five for Maybach as the carmaker bets on rising wealth and luxury demand

Tata Motors charts shift to software-led vehicles with t.idal platform

SDV strategy to complement pipeline of new launches across ICE, CNG and EV segments

Biopharma entering innovation power decade, says Bernstein report

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Small cars, SUVs drive passenger vehicle sales to record high in May

Scooters powered highest-ever 2W volumes, shows Siam data

Novartis brings India's first 'guided missile' therapy for prostate cancer

Novartis launches Pluvicto, a precision treatment that delivers radiation directly to cancer cells

Mercedes to expand PHEV line-up as buyers still prefer conventional cars

Mercedes-Benz India said plug-in hybrids could play a bigger role in its portfolio as most luxury-car buyers continue to favour conventional powertrains despite rising electric-vehicle adoption

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Wockhardt targets 50% of revenue from novel drugs within five years

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

Cancer drug shortage: Drugmaker Naprod seeks one-time price hike

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

Electric vehicle retail sales up 45% in May; ePVs and e2Ws drove adoption

India's EV sales surged 45% to a record 2.72 lakh units in May, pushing overall EV penetration above 11% for the first time amid rising fuel costs

Drug companies seek NPPA price revision for cancer drugs amid shortage

Oncology drugmaker says soaring platinum prices, higher import duties and lengthy import approvals have made production financially unviable, worsening shortages of key chemotherapy medicines

M&M bets beyond tractors to drive farm mechanisation and rural enterprise

Expands focus beyond tractors into harvesters, seed drills and telematics-led services

Services, digital business emerge as drivers of TaMo CV arm's earnings

Iveco seen as technology and global expansion platform; EVs and hydrogen remain central to future strategy